# SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT04948788** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 102 (estimated)

## Conditions studied

- Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** SHR1459 ；YY-20394
- **DRUG:** SHR1459 ；YY-20394
- **DRUG:** Gemcitabine-Oxaliplatin

## Key facts

- **NCT ID:** NCT04948788
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10
- **Primary completion:** 2023-04
- **Final completion:** 2023-10
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948788, "SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04948788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*